Marker Therapeutics (MRKR) Enterprise Value (2016 - 2025)
Marker Therapeutics (MRKR) has disclosed Enterprise Value for 11 consecutive years, with -$1.4 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 84.97% to -$1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.9 million, a 67.91% increase, with the full-year FY2024 number at -$19.2 million, down 27.01% from a year prior.
- Enterprise Value was -$1.4 million for Q3 2025 at Marker Therapeutics, roughly flat from -$1.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$181864.0 in Q1 2022 to a low of -$64.5 million in Q1 2021.
- A 5-year average of -$20.6 million and a median of -$15.1 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: soared 99.72% in 2022, then tumbled 3419.8% in 2023.
- Marker Therapeutics' Enterprise Value stood at -$43.5 million in 2021, then surged by 72.91% to -$11.8 million in 2022, then decreased by 28.26% to -$15.1 million in 2023, then decreased by 27.01% to -$19.2 million in 2024, then skyrocketed by 92.95% to -$1.4 million in 2025.
- Per Business Quant, the three most recent readings for MRKR's Enterprise Value are -$1.4 million (Q3 2025), -$1.4 million (Q2 2025), and -$13.7 million (Q1 2025).